公开(公告)号：US20220056093A1

公开(公告)日：2022-02-24

申请号：US17275662

申请日：2019-09-11

申请人： Ambrx, Inc.

发明人： Sigeng CHEN ,  Yingchun Lu ,  MD Harunur Rashid ,  Nickolas Knudsen ,  Feng Tian

IPC分类号： C07K14/55 ,  A61K47/60

摘要： The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.

公开(公告)号：US11578111B2

公开(公告)日：2023-02-14

申请号：US16754357

申请日：2018-10-10

申请人： Elanco US Inc. ,  Ambrx, Inc.

发明人： Peter Connor Canning ,  Nickolas Knudsen ,  Md Harunur Rashid

IPC分类号： C07K14/535 ,  A61K47/60 ,  A61P37/04 ,  A61P31/04 ,  A61K38/19

摘要： The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.

公开(公告)号：US20220033518A1

公开(公告)日：2022-02-03

申请号：US17003952

申请日：2020-08-26

申请人： Ambrx,Inc.

发明人： Richard Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nickolas Knudsen ,  Andrew Beck ,  Ying Sun

IPC分类号： C07K16/40 ,  C07K16/30 ,  C07K5/02 ,  A61K47/68

摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US20220009986A1

公开(公告)日：2022-01-13

申请号：US17285896

申请日：2019-10-19

申请人： Ambrx, Inc.

发明人： Mingchao Kang ,  Yingchun Lu ,  Nickolas Knudsen ,  MD Harunur Rashid ,  Feng Tian

IPC分类号： C07K14/54 ,  C07K19/00 ,  A61K45/06 ,  A61K47/65

摘要： The present invention provides methods for targeting interleukin-10 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-10 (IL-10) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-10 receptor.

公开(公告)号：US10960080B2

公开(公告)日：2021-03-30

申请号：US16311540

申请日：2017-06-16

申请人： ELANCO US INC. ,  AMBRX, INC.

发明人： Peter Connor Canning ,  Nickolas Knudsen ,  Lillian Skidmore

IPC分类号： A61K47/60 ,  C07K14/56 ,  A61P31/14 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K38/00

摘要： Disclosed herein are porcine interferon alpha variants (pIFN-α) comprising a synthetic amino acid at select locations in pIFN-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pIFN-α variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.